Title :

Rituximab and cyclophosphamide in antisynthetase syndrome-related interstitial lung disease: an observational retrospective study

Author(s) :

Langlois, Vincent [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Gillibert, Andre [Auteur]
Unité de Biostatistiques [CHU Rouen]
Uzunhan, Yurdagul [Auteur]
Service de pneumologie [Avicenne]
Chabi-Charvillat, Marie-Laure [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Hachulla, Eric [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Landon-Cardinal, Oceane [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Mariampillai, Kuberaka [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Champtiaux, Nicolas [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Nunes, Hilario [Auteur]
Hôpital Avicenne [AP-HP]
Benveniste, Olivier [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Hervier, Baptiste [Auteur]
CHU Pitié-Salpêtrière [AP-HP]

Journal title :

The Journal of rheumatology

Abbreviated title :

J. Rheumatol.

Publication date :

2020-03-15

ISSN :

0315-162X

Keyword(s) :

interstitial lung disease
antisynthetase syndrome
cyclophosphamide
rituximab

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Antisynthetase syndrome (AS)-related interstitial lung disease (ILD) has a poor prognosis. Intravenous cyclophosphamide (IV CYC) and rituximab (RTX) are the main treatments currently used for moderate to severe ILD. Here, ...
Show more >Antisynthetase syndrome (AS)-related interstitial lung disease (ILD) has a poor prognosis. Intravenous cyclophosphamide (IV CYC) and rituximab (RTX) are the main treatments currently used for moderate to severe ILD. Here, we compare the efficacy of CYC followed by standard immunosuppressive treatment (IST) versus RTX in AS-related ILD. This observational retrospective study was conducted between 2003 and 2016 in 3 tertiary care centers. All patients with AS-related ILD and treated with CYC or RTX with at least 6 months of follow-up were included. Pulmonary progression-free survival (PFS), defined according to the American Thoracic Society guidelines, was assessed at 6 months and 2 years. All severe adverse events (AE) were recorded. Sixty-two patients were included. Thirty-four patients received 2-12 monthly IV CYC pulses, followed by standard IST in 30 cases (88%). The RTX group included 28 patients. Following the initial Day 1 to Day 15 infusions, RTX was repeated every 6 months in 26 cases (93%) and 15 patients (54%) concomitantly received another IST. The median steroid dose was similar between both groups. Although RTX and CYC demonstrated similar PFS at 6 months (92% vs 85%, respectively), RTX was superior at 2 years (HR 0.263, 95% CI 0.094-0.732, PP Despite similar PFS at 6 months, RTX was associated with a better 2-year PFS compared to CYC in patients with AS-related ILD.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2021-07-06T12:48:14Z
2024-03-28T10:30:56Z